How Is Hims & Hers Health (NYSE:HIMS) Performing in the Market?

2 min read | February 28, 2025 03:50 AM AEDT | By Team Kalkine Media

Google News:

How Is Hims & Hers Health (NYSE:HIMS) Performing in the Market? — Image source: Shutterstock

Recent News

Why Energy Stocks Are Facing A Cash-Flow Reality Check

Is The Hormuz Reset Repricing ASX Oil And Gas Stocks?

Rare Earth Breakthrough: How Lynas Is Challenging China's Dominance

Rare Earth Rush: Why ASX Critical Minerals Stocks Are Surging

Make Kalkine Media
My Trusted Source

Highlights

Hims & Hers Health has received varied ratings, reflecting different market perspectives.

The stock has shown significant movement, influenced by institutional investments and insider activity.

The telehealth platform continues expanding its offerings, strengthening its market presence.

Stock Performance and Market Activity

Hims & Hers Health (NYSE:HIMS) has seen varied ratings from financial institutions, reflecting shifting market perspectives. Leerink Partners adjusted its price target from $24 to $40, maintaining a neutral stance. Morgan Stanley revised its rating from overweight to equal weight while raising its price target to $60. Deutsche Bank Aktiengesellschaft and Piper Sandler provided cautious assessments but still increased their targets, signaling refined expectations amid evolving trends.

The stock recently opened at $41.87 and has demonstrated a broad trading range, fluctuating between $11.20 and $72.98 over the past year. This volatility highlights changing investor sentiment regarding the company’s place in the healthcare sector.

Financial Metrics and Earnings

Hims & Hers Health posted earnings per share of $0.11, surpassing forecasts. The company maintains a net margin of 8.19% and a return on equity of 10.97%. Revenue for the latest quarter reached $481.14 million, slightly below expectations of $494.56 million. Despite this, the company continues to exhibit financial resilience within the telehealth sector.

Institutional Transactions and Market Engagement

Recent filings indicate shifts in stock holdings among company personnel. Transactions include Michael Chisold’s sale of shares valued at over $68,000 and a significant sale by Soleil Boughton, reflecting financial adjustments within the organization.

Institutional investors have also modified their holdings, signaling ongoing market interest. Firms such as Main Management ETF Advisors LLC and Robeco Institutional Asset Management B.V. have increased their positions, showing active participation in the company's market standing.

Market Presence and Business Expansion

Founded in 2017 and headquartered in San Francisco, Hims & Hers Health operates as a telehealth platform offering services in dermatology, mental health, primary care, and more. The company’s digital healthcare expansion continues to attract industry attention, reinforcing its role in online medical services.

With increasing demand for accessible healthcare solutions, Hims & Hers Health continues refining its offerings and broadening its reach. Its growth strategy involves scaling services, enhancing platform capabilities, and adapting to evolving patient needs.

As the telehealth industry evolves, Hims & Hers Health remains positioned for long-term relevance through innovation and a customer-centric approach. Its ability to navigate market shifts and sustain financial performance underscores its role in shaping digital healthcare.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.